RadNet Stock (NASDAQ:RDNT)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$71.38

52W Range

$33.44 - $93.65

50D Avg

$74.86

200D Avg

$62.09

Market Cap

$5.38B

Avg Vol (3M)

$520.47K

Beta

1.75

Div Yield

-

RDNT Company Profile


RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

10,000

IPO Date

Jan 03, 1997

Website

RDNT Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Software and Teleradiology$18.08M$14.24M-
Workers' Compensation/Personal Injury1$47.36M$51.34M$44.23M
Medicare1$363.86M$311.12M$280.91M
Medicaid1$43.17M$38.28M$34.73M
Health Care, Patient Service Other$42.25M$31.85M$19.40M
Health Care, Other$20.11M$19.43M$13.85M
Health Care, Management Service$17.94M$22.23M$19.63M
Commercial Insurance1$897.95M$785.13M$743.46M
Capitation Arrangements$153.43M$152.04M$148.33M
Imaging On Call--$10.53M
Health Care, Patient Service--$1.17B

Fiscal year ends in Dec 23 | Currency in USD

RDNT Financial Summary


Dec 23Dec 22Dec 21
Revenue$1.62B$1.43B$1.32B
Operating Income$98.70M$46.36M$82.55M
Net Income$47.28M$33.61M$44.32M
EBITDA$1.50B$243.12M$264.73M
Basic EPS-$0.59$0.83
Diluted EPS-$0.59$0.83

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 11, 24 | 10:34 PM
Q2 24Aug 08, 24 | 7:45 PM
Q1 24May 09, 24 | 12:00 AM

Peer Comparison


TickerCompany
SERASera Prognostics, Inc.
QGENQiagen N.V.
ACRSAclaris Therapeutics, Inc.
BDSXBiodesix, Inc.
XGNExagen Inc.
BNRBurning Rock Biotech Limited
NEOGNeogen Corporation
FONRFONAR Corporation
MYGNMyriad Genetics, Inc.
SHCSotera Health Company